Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

NCT05289687 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

NETWORK

Sponsor class

Conditions

T-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: Daratumumab / Hyaluronidase Injection
DRUG: Daratumumab / Hyaluronidase Injection
DRUG: Daratumumab / Hyaluronidase Injection
DRUG: Daratumumab / Hyaluronidase Injection

Sponsor

Eastern Cooperative Oncology Group

Collaborators

[object Object]